In this new blog series, we review ISO 14971 (Application of risk management to medical devices) - its history, the principles embedded within it and how it relates to other standards and regulation. For the first editio...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICER's Growing Impact On Drug Pricing And Reimbursement
Read Forbes' original article referencing the ICON whitepaper ‘The Role of ICER as an Independent HTA Organisation’, exploring how ICER may have a greater impact on payer decision-making than expected and can be viewed as a ‘decision resource’ for budgetary and formulary policy decision making.
-
The rise of patient-centricity
In the April 2019 issue of Pharmaceutical Market Europe (PME), p.32-34, Matt McCarty discusses the importance of understanding what patients value and ways to gather patient insights.
-
ICON CIO – Telemedicine, Wearables & AI Could Boost Clinical Trial Participation
A Diginomica article featuring commentary from ICON's Tom O’Leary, discussing the opportunities for technology to overcome key challenges in clinical trials, such as retention and diversity, by making participation less burdensome for patients.
-
Embracing Digital Health
A thought leadership article by Vicki Anastasi, Matt McCarty and Marie McCarthy, published by the Journal of mHealth, on the skills and expertise needed to best use mHealth to transform clinical trials, thereby improving the efficacy of therapies in the real world and increasing pharma R&D productivity.
-
Converging Goals: How a Focus on the Patient Drives Stronger Healthcare Partnerships
The foundation of healthcare is shifting from a provider-based to a patient-centric, or value-based, model. With aging populations, better-informed patients, and emerging technologies, the responsibilities and roles of every stakeholder in this industry is changing. Gain further insights on this topic from ICON expert Vicki Anastasi (VP, Global Head, Medical Device and Diagnostics Research, Real World Evidence Late Phase Research) in this recent MPO Magazine article.
-
How ICON is Using Analytics & Wearables to Enhance Clinical Trials
Read Computer Weekly's recent ICON article to learn how our company is investing in emergent technology to boost the attractiveness of trials as a care option and attract more participants, while enhancing internal efficiency around drug and device development.
-
Patients is a Virtue
As patients are increasingly using digital and social media as part of their consumer behaviour, it becomes important for healthcare to also be digitally enabled. In order to truly understand the value of direct patient engagement and advocacy, pharma companies need to take the time to understand how to grow successful, mutually beneficial relationships.
-
Navigating the Labyrinth of Regulation and Taking Drug Safety Reporting to the Next Level with Automation
An article published by Pharma focus, authored by ICON experts Arinder Sihota, PhD and Beata Kolon, on the challenges of global clinical trials in an ever-changing regulatory environment and the advantages of applying innovative automation to safety reporting.
-
Next generation of clinical trials
In this edition of Pharma Times, ICON's Tom O’Leary contributes to the discussion on the next generation of clinical trials in particular participant engagement, expansive data and the use of digital technology for patients and pharma.
-
Special Report on Immunology & Autoimmunity: Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from Marco Silleni, discussing the challenges of autoimmune disorders. Silleni mentions the potential for extended therapy often means that regulatory authorities are much more focused on chronic toxicities and the requirement of long-term safety data. In addition, chronic autoimmunity diseases often mean lengthy trials and clinical monitoring, therefore the qualifications and skills of assessors are paramount.
